Decision Competitors
| DECN Stock | USD 0.0001 0.00 0.000003% |
Decision Diagnostics vs AXM Pharma Correlation
As of the 12th of February 2026, Return On Tangible Assets is likely to grow to -13.34. In addition to that, Return On Capital Employed is likely to grow to -2.48. At this time, Decision Diagnostics' Other Current Assets are very stable compared to the past year. As of the 12th of February 2026, Total Current Assets is likely to grow to about 2.5 M, while Total Assets are likely to drop about 5.2 M.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Decision Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Decision Diagnostics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Decision Diagnostics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Decision and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Decision Diagnostics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Decision Stock performing well and Decision Diagnostics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Decision Diagnostics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ROTH | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| AMBS | 1.99 | (0.87) | 0.00 | 0.49 | 0.00 | 0.00 | 66.67 | |||
| PRMD | 1.99 | 0.99 | 0.00 | 7.65 | 0.00 | 0.00 | 66.67 | |||
| ITMC | 4.48 | 1.04 | 0.00 | (1.83) | 0.00 | 0.00 | 100.00 | |||
| IBXG | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| WIBFF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SXHHF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| LGND | 1.53 | (0.17) | 0.00 | (0.90) | 0.00 | 3.36 | 12.56 | |||
| RGDXQ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| AXMP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cross Equities Net Income Analysis
Compare Decision Diagnostics and related stocks such as Pharmaroth Labs, Amarantus Bioscience, and Primemd Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROTH | (10.7 K) | (370 K) | (370 K) | (370 K) | (370 K) | (232.8 K) | (91.5 K) | (91.5 K) | (91.5 K) | (91.5 K) | (91.5 K) | (91.5 K) | (91.5 K) | (91.5 K) | (91.5 K) | (82.4 K) | (86.5 K) |
| IBXG | (791.2 K) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.2 M) | (3.1 M) |
| LGND | (27.1 M) | 10.2 M | (527 K) | 11.4 M | 12 M | 257.3 M | (1.6 M) | 12.6 M | 143.3 M | 629.3 M | (3 M) | 57.1 M | (33.4 M) | 52.2 M | (4 M) | (4.6 M) | (4.4 M) |
Decision Diagnostics and related stocks such as Pharmaroth Labs, Amarantus Bioscience, and Primemd Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Decision Diagnostics financial statement analysis. It represents the amount of money remaining after all of Decision Diagnostics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Decision Diagnostics Competitive Analysis
The better you understand Decision Diagnostics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Decision Diagnostics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Decision Diagnostics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Decision Diagnostics Competition Performance Charts
Five steps to successful analysis of Decision Diagnostics Competition
Decision Diagnostics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Decision Diagnostics in relation to its competition. Decision Diagnostics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Decision Diagnostics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Decision Diagnostics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Decision Diagnostics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Decision Diagnostics position
In addition to having Decision Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Decision Diagnostics Correlation with its peers. To learn how to invest in Decision Stock, please use our How to Invest in Decision Diagnostics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Health Care Technology sector continue expanding? Could Decision diversify its offerings? Factors like these will boost the valuation of Decision Diagnostics. Projected growth potential of Decision fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Decision Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.02) | Revenue Per Share | Quarterly Revenue Growth (0) | Return On Assets | Return On Equity |
Understanding Decision Diagnostics requires distinguishing between market price and book value, where the latter reflects Decision's accounting equity. The concept of intrinsic value - what Decision Diagnostics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Decision Diagnostics' price substantially above or below its fundamental value.
It's important to distinguish between Decision Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Decision Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Decision Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.